-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 6, the official website of the State Food and Drug Administration showed that Hainan Beite Pharmaceutical Co.
, Ltd.
was the fifth domestically produced voriconazole for injection, which was approved for production as a copy of Category 4
.
According to data from Minet.
com, the sales of this variety in public medical institutions in China will exceed 2 billion yuan in 2020
.
, Ltd.
was the fifth domestically produced voriconazole for injection, which was approved for production as a copy of Category 4
.
According to data from Minet.
com, the sales of this variety in public medical institutions in China will exceed 2 billion yuan in 2020
.
Source: State Food and Drug Administration official website
Voriconazole is a broad-spectrum triazole antifungal that inhibits cytochrome P450-mediated demethylation of 14α-sterols in fungi, thereby inhibiting ergosterol biosynthesis, ultimately leading to fungal cell death
.
It is clinically used for the treatment of invasive aspergillosis, severe invasive infections caused by fluconazole-resistant Candida (including Candida krusei), and severe infections caused by Actinomyces pedis and Fusarium spp
.
.
It is clinically used for the treatment of invasive aspergillosis, severe invasive infections caused by fluconazole-resistant Candida (including Candida krusei), and severe infections caused by Actinomyces pedis and Fusarium spp
.
The main dosage forms of voriconazole that have been marketed in China include injections, tablets, capsules, etc.
According to Minet data, in 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminal voriconazole The market size exceeds 4 billion yuan, of which voriconazole for injection occupies "half of the country"
.
According to Minet data, in 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminal voriconazole The market size exceeds 4 billion yuan, of which voriconazole for injection occupies "half of the country"
.
In recent years, among the terminal systemic antifungal chemical products in China's public medical institutions, voriconazole for injection has ranked first.
Judging from the competition pattern of manufacturers of this variety, the original manufacturer Pfizer has long dominated the market, but its market share has a downward trend
.
Judging from the competition pattern of manufacturers of this variety, the original manufacturer Pfizer has long dominated the market, but its market share has a downward trend
.
Voriconazole for Injection is newly classified and reported for production and is under review
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
At present, more than ten companies have submitted voriconazole for injection marketing applications under the 4 categories of imitations.
Among them, the products of Hainan Beite Pharmaceutical have been approved for production and have been deemed to have passed the evaluation, making it the fifth domestic company and the first to pass the evaluation; Dakang Huakang Pharmaceutical has submitted a supplementary application for the consistency evaluation of voriconazole for injection, which is currently under review and approval
.
Among them, the products of Hainan Beite Pharmaceutical have been approved for production and have been deemed to have passed the evaluation, making it the fifth domestic company and the first to pass the evaluation; Dakang Huakang Pharmaceutical has submitted a supplementary application for the consistency evaluation of voriconazole for injection, which is currently under review and approval
.
Bite's Reviewed Systemic Antifungal
Source: new version database of Minet
According to the data of Minet.
com, in the field of systemic antifungal drugs, Beite Pharmaceuticals has 2 varieties that have passed or are deemed to have passed the consistency evaluation, both of which are the first
.
com, in the field of systemic antifungal drugs, Beite Pharmaceuticals has 2 varieties that have passed or are deemed to have passed the consistency evaluation, both of which are the first
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
Note: The statistics are as of April 6.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
On April 6, the official website of the State Food and Drug Administration showed that Hainan Beite Pharmaceutical Co.
, Ltd.
was the fifth domestically produced voriconazole for injection, which was approved for production as a copy of Category 4
.
According to data from Minet.
com, the sales of this variety in public medical institutions in China will exceed 2 billion yuan in 2020
.
, Ltd.
was the fifth domestically produced voriconazole for injection, which was approved for production as a copy of Category 4
.
According to data from Minet.
com, the sales of this variety in public medical institutions in China will exceed 2 billion yuan in 2020
.
Source: State Food and Drug Administration official website
Voriconazole is a broad-spectrum triazole antifungal that inhibits cytochrome P450-mediated demethylation of 14α-sterols in fungi, thereby inhibiting ergosterol biosynthesis, ultimately leading to fungal cell death
.
It is clinically used for the treatment of invasive aspergillosis, severe invasive infections caused by fluconazole-resistant Candida (including Candida krusei), and severe infections caused by Actinomyces pedis and Fusarium spp
.
.
It is clinically used for the treatment of invasive aspergillosis, severe invasive infections caused by fluconazole-resistant Candida (including Candida krusei), and severe infections caused by Actinomyces pedis and Fusarium spp
.
The main dosage forms of voriconazole that have been marketed in China include injections, tablets, capsules, etc.
According to Minet data, in 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminal voriconazole The market size exceeds 4 billion yuan, of which voriconazole for injection occupies "half of the country"
.
According to Minet data, in 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminal voriconazole The market size exceeds 4 billion yuan, of which voriconazole for injection occupies "half of the country"
.
In recent years, among the terminal systemic antifungal chemical products in China's public medical institutions, voriconazole for injection has ranked first.
Judging from the competition pattern of manufacturers of this variety, the original manufacturer Pfizer has long dominated the market, but its market share has a downward trend
.
Judging from the competition pattern of manufacturers of this variety, the original manufacturer Pfizer has long dominated the market, but its market share has a downward trend
.
Voriconazole for Injection is newly classified and reported for production and is under review
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
At present, more than ten companies have submitted voriconazole for injection marketing applications under the 4 categories of imitations.
Among them, the products of Hainan Beite Pharmaceutical have been approved for production and have been deemed to have passed the evaluation, making it the fifth domestic company and the first to pass the evaluation; Dakang Huakang Pharmaceutical has submitted a supplementary application for the consistency evaluation of voriconazole for injection, which is currently under review and approval
.
Among them, the products of Hainan Beite Pharmaceutical have been approved for production and have been deemed to have passed the evaluation, making it the fifth domestic company and the first to pass the evaluation; Dakang Huakang Pharmaceutical has submitted a supplementary application for the consistency evaluation of voriconazole for injection, which is currently under review and approval
.
Bite's Reviewed Systemic Antifungal
Source: new version database of Minet
According to the data of Minet.
com, in the field of systemic antifungal drugs, Beite Pharmaceuticals has 2 varieties that have passed or are deemed to have passed the consistency evaluation, both of which are the first
.
com, in the field of systemic antifungal drugs, Beite Pharmaceuticals has 2 varieties that have passed or are deemed to have passed the consistency evaluation, both of which are the first
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
Note: The statistics are as of April 6.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
On April 6, the official website of the State Food and Drug Administration showed that Hainan Beite Pharmaceutical Co.
, Ltd.
was the fifth domestically produced voriconazole for injection, which was approved for production as a copy of Category 4
.
According to data from Minet.
com, the sales of this variety in public medical institutions in China will exceed 2 billion yuan in 2020
.
, Ltd.
was the fifth domestically produced voriconazole for injection, which was approved for production as a copy of Category 4
.
According to data from Minet.
com, the sales of this variety in public medical institutions in China will exceed 2 billion yuan in 2020
.
Source: State Food and Drug Administration official website
Voriconazole is a broad-spectrum triazole antifungal that inhibits cytochrome P450-mediated demethylation of 14α-sterols in fungi, thereby inhibiting ergosterol biosynthesis, ultimately leading to fungal cell death
.
It is clinically used for the treatment of invasive aspergillosis, severe invasive infections caused by fluconazole-resistant Candida (including Candida krusei), and severe infections caused by Actinomyces pedis and Fusarium spp
.
.
It is clinically used for the treatment of invasive aspergillosis, severe invasive infections caused by fluconazole-resistant Candida (including Candida krusei), and severe infections caused by Actinomyces pedis and Fusarium spp
.
The main dosage forms of voriconazole that have been marketed in China include injections, tablets, capsules, etc.
According to Minet data, in 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminal voriconazole The market size exceeds 4 billion yuan, of which voriconazole for injection occupies "half of the country"
.
hospital hospital hospitalAccording to Minet data, in 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminal voriconazole The market size exceeds 4 billion yuan, of which voriconazole for injection occupies "half of the country"
.
In recent years, among the terminal systemic antifungal chemical products in China's public medical institutions, voriconazole for injection has ranked first.
Judging from the competition pattern of manufacturers of this variety, the original manufacturer Pfizer has long dominated the market, but its market share has a downward trend
.
Judging from the competition pattern of manufacturers of this variety, the original manufacturer Pfizer has long dominated the market, but its market share has a downward trend
.
Voriconazole for Injection is newly classified and reported for production and is under review
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
At present, more than ten companies have submitted voriconazole for injection marketing applications under the 4 categories of imitations.
Among them, the products of Hainan Beite Pharmaceutical have been approved for production and have been deemed to have passed the evaluation, making it the fifth domestic company and the first to pass the evaluation; Dakang Huakang Pharmaceutical has submitted a supplementary application for the consistency evaluation of voriconazole for injection, which is currently under review and approval
.
enterprise enterprise enterpriseAmong them, the products of Hainan Beite Pharmaceutical have been approved for production and have been deemed to have passed the evaluation, making it the fifth domestic company and the first to pass the evaluation; Dakang Huakang Pharmaceutical has submitted a supplementary application for the consistency evaluation of voriconazole for injection, which is currently under review and approval
.
Bite's Reviewed Systemic Antifungal
Source: new version database of Minet
According to the data of Minet.
com, in the field of systemic antifungal drugs, Beite Pharmaceuticals has 2 varieties that have passed or are deemed to have passed the consistency evaluation, both of which are the first
.
com, in the field of systemic antifungal drugs, Beite Pharmaceuticals has 2 varieties that have passed or are deemed to have passed the consistency evaluation, both of which are the first
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
Note: The statistics are as of April 6.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
